Publication date: 05/06/2018
Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announced that it has signed a binding Heads of Terms agreement with Hyundai Pharm, a South Korean Women’s Health leader, for an exclusive license to commercialize Estelle® in South Korea. Estelle® is Mithra’s novel combined oral contraceptive (COC) product candidate currently in pivotal Phase III trials in Europe and Russia as well as in the US and Canada, with top line results expected in Q3 2018 and Q1 2019, respectively.
Under the terms of the agreement, Mithra will be eligible for milestone payments, Minimal Annual Quantities (MAQ) and further sales-related royalties. Moreover, Mithra will produce Estelle® for the South Korean market at its CDMO.
The South Korean contraceptive market is worth approximately EUR 36 million a year, with Combined Oral Contraceptives (COCs) accounting for EUR 27 million.
Hyundai Pharm Co. Ltd. (listed on the Korean market as KR:004310), headquartered in Seoul, Korea, is a leading manufacturer and distributor of pharmaceutical products, health food drinks and medical equipment. The company was founded in 1965 and reported total revenues of USD 130 million in 2017. Women’s Health is one of Hyundai Pharm’s key focus areas, including a range of products for emergency contraception, morning sickness and Hormone Treatment (HT). The company has been steadily expanding its Women’s Health franchise, and aims to launch Estelle® as a fifth-generation oral contraceptive in South Korea. Moreover, Hyundai Pharm is prepared to significantly invest in bringing Estelle® to market, with the clear intention to grow a still relatively small South Korean contraceptive market using Mithra’s novel contraceptive.
François Fornieri, CEO of Mithra, commented: “We are very pleased to have agreed terms with Hyundai Pharm for the commercialization of Estelle® in South Korea. With their increasing focus on Women’s Health, we are confident that Hyundai Pharm is the best possible partner for the commercialization of Estelle®. Hyundai is a top three Women's Health company in Korea, and the fastest growing one, with a CAGR of over 21% over the last three years.
“Following contracts with Fuji Pharma in Japan, Libbs in Brazil and Searchlight in Canada, we continue to deliver on our strategy to create key partnerships with Women's Health leaders around the world. We will continue to pursue this best-in-class approach as we select partners in the core territories of Europe and the US to maximize the potential of our blockbuster candidates, Estelle® for contraception and Donesta® for menopause.”
Estelle® is Mithra’s novel oral contraceptive product candidate composed of 15 mg Estetrol (E4), its unique native estrogen, and 3 mg DRSP. Currently, pivotal Phase III Estelle® trials (E4 Freedom) are ongoing in Europe and Russia as well as in the US and Canada, with top line results expected in Q3 2018 and Q1 2019, respectively.
The E4 Freedom studies are open-label single arm trials to assess the safety and efficacy of Estelle® in over 1,550 participants in Europe/Russia and approximately 2,000 participants in the US/Canada, over a period of 13 cycles. Patient enrolment has been completed for both pivotal studies.
Hyundai Pham Co. Ltd. (listed on the Korean market as KR:004310), headquartered in Seoul, Korea, is a leading manufacturer and distributor of pharmaceutical products, health food drinks and medical equipment. The company has been founded in 1965, and reported revenues of USD 130m in 2017. The Hyundai team is committed to being a market creator, foreseeing unmet medical needs and pioneering new market opportunities. Women’s Health is one of their key focus areas.
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO.
Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com